Literature DB >> 10397217

The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters.

P E Marik1, G Abraham, P Careau, J Varon, R E Fromm.   

Abstract

OBJECTIVE: Catheter-related sepsis is an important complication associated with the use of central venous catheters. Recent studies have suggested that antimicrobial-bonded catheters may reduce catheter colonization and catheter-related sepsis. The aim of this study was to determine the relationship between the antimicrobial activity and the colonization rate of two commercially available antimicrobial-bonded central venous catheters.
DESIGN: Prospective, randomized, controlled, nonblinded study.
SETTING: Medical intensive care unit of a university-affiliated teaching hospital. PATIENTS: One hundred twenty consecutive medical intensive care unit patients requiring new central venous catheters (fresh stick).
INTERVENTIONS: Patients were randomized to receive a) a Standard Arrow; b) an ARROWgard; or c) a Cook Bio-Guard Spectrum central venous catheter. Central venous catheters were removed when they were no longer required or when catheter-related sepsis was suspected. Under aseptic conditions, the distal 12 cm of the removed catheters were cut into six 2-cm segments. Semiquantitative culture was performed (by roll technique) on the distal segment. Colonization was defined as >15 colony-forming units. Using a modified Kirby-Bauer technique, the zone of inhibition of the remaining five segments was determined against the following organisms: methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis, Enterococcus faecalis, Acinetobacter baumannii, and Candida albicans Catheters that were removed within 24 hrs of insertion were excluded from the analysis.
MEASUREMENTS AND MAIN RESULTS: Seven patients were not assessable. The baseline clinical and demographic characteristics were similar among the three groups of patients. Eleven Standard Arrow (28%), seven ARROWgard (19%), and four Bio-Guard (11%) catheters were colonized (p = .05 for Bio-Guard vs. control). Staphylococci were the most common colonizing organisms. Two patients with Standard Arrow catheters (5%) and one patient with an ARROWgard catheter (3%) developed catheter-related sepsis. Antibiotic-coated catheters significantly inhibited the growth of all test organisms except C. albicans (p < or = .05). Zones of inhibition were significantly larger for the Bio-Guard compared with the ARROWgard catheter when tested against MRSA, S. epidermidis, and E. faecalis (p < or = .002).
CONCLUSION: The Bio-Guard central venous catheter had greater ex vivo antimicrobial activity against MRSA, S. epidermidis, and E. faecalis compared with the ARROWgard catheter, and this was associated with a significantly lower rate of catheter colonization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397217     DOI: 10.1097/00003246-199906000-00034

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  13 in total

1.  Antimicrobial activity of prosthetic heart valve sewing cuffs coated with minocycline and rifampin.

Authors:  Rabih O Darouiche; Vance G Fowler; Karim Adal; Marcia Kielhofner; David Mansouri; L Barth Reller
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 2.  Catheter-associated infections: pathogenesis affects prevention.

Authors:  Barbara W Trautner; Rabih O Darouiche
Journal:  Arch Intern Med       Date:  2004-04-26

Review 3.  Anti-infective-treated central venous catheters: a systematic review of randomized controlled trials.

Authors:  B S Niël-Weise; T Stijnen; P J van den Broek
Journal:  Intensive Care Med       Date:  2007-10-17       Impact factor: 17.440

4.  Antimicrobial impregnated catheters in the prevention of catheter-related bloodstream infection in hospitalized patients.

Authors:  Sarah K Wassil; Catherine M Crill; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2007-04

5.  Prolonged antimicrobial activity of a catheter containing chlorhexidine-silver sulfadiazine extends protection against catheter infections in vivo.

Authors:  S Bassetti; J Hu; R B D'Agostino; R J Sherertz
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial.

Authors:  Cristóbal León; Sergio Ruiz-Santana; Jordi Rello; Maria V de la Torre; Jordi Vallés; Francisco Alvarez-Lerma; Rafael Sierra; Pedro Saavedra; Francisco Alvarez-Salgado
Journal:  Intensive Care Med       Date:  2004-07-20       Impact factor: 17.440

Review 7.  New horizon for infection prevention technology and implantable device.

Authors:  Yusuke Kondo; Marehiko Ueda; Yoshio Kobayashi; Joerg O Schwab
Journal:  J Arrhythm       Date:  2016-03-19

Review 8.  Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults.

Authors:  Nai Ming Lai; Nathorn Chaiyakunapruk; Nai An Lai; Elizabeth O'Riordan; Wilson Shu Cheng Pau; Sanjay Saint
Journal:  Cochrane Database Syst Rev       Date:  2016-03-16

9.  Impact of catheter antimicrobial coating on species-specific risk of catheter colonization: a meta-analysis.

Authors:  Aleksey Novikov; Manuel Y Lam; Leonard A Mermel; Anna L Casey; Tom S Elliott; Peter Nightingale
Journal:  Antimicrob Resist Infect Control       Date:  2012-12-03       Impact factor: 4.887

10.  Antimicrobial-impregnated central venous catheters for preventing neonatal bloodstream infection: the PREVAIL RCT.

Authors:  Ruth Gilbert; Michaela Brown; Rita Faria; Caroline Fraser; Chloe Donohue; Naomi Rainford; Alessandro Grosso; Ajay K Sinha; Jon Dorling; Jim Gray; Berit Muller-Pebody; Katie Harron; Tracy Moitt; William McGuire; Laura Bojke; Carrol Gamble; Sam J Oddie
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.